Teva Pharmaceutical Industries Ltd to Discuss New Data Presented for Duvakitug (Anti-TL1A) Phase 2b after ECCO Conference Call Transcript
Good morning or good afternoon, all, and welcome to the duvakitug anti-TL1A phase IIb data presentation from ECCO. My name is Adam, and I'll be your operator today. (Operator Instructions)
I will now hand the floor to Chris Stevo to begin. So Chris, please go ahead when you're ready.
Thank you very much, Adam. Good morning, and good afternoon, everyone. Thank you for joining us to discuss these important data. We'll be making forward-looking statements in the course of this call. Any statements we make are only as of today, and we do not undertake any obligation to update these statements beyond this call. If you have questions about our forward-looking statements or risk factors, please see our SEC filings under Forms 10-K and 10-Q.
And with that, I will turn it over to our host, Dr. Eric Hughes. Go ahead, Eric.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
